BridgeMD
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab in combination with Oral Trifluridine and Tipiracil in Adult Participants with Refractory Metastatic Colorectal Cancer
EU CTIS ID: 2025-521712-19-00
What this study is testing
- To demonstrate the superiority of telisotuzumab adizutecan + bevacizumab over trifluridine and tipiracil + bevacizumab in terms of Objective Response (OR). - To demonstrate the superiority of telisotuzumab adizutecan + bevacizumab over trifluridine and tipiracil + bevacizumab in terms of Overall Survival (OS).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Must voluntarily sign and date an informed consent, approved by an Ethics Committee (IEC)/ Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Participants must have the capacity to consent in the opinion of the investigator.
- Life expectancy >= 12 weeks per investigator assessment
You likely can't join if
- Prior systemic regimen containing c-Met targeting agent (e.g., antibody, antibody drug conjugate, bispecific) or any other unapproved investigational agent.
- History of allergic reactions or hypersensitivity to bevacizumab or any of its excipients, or to compounds similar to trifluridine/tipiracil.
- History of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
- History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months.
The study team makes the final eligibility decision.
Where it's taking place
- Taiwan
- Japan
- United States
- Brazil
- Korea, Republic of
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taiwan; Japan; United States; Brazil; Korea, Republic of; China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.